Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital (2015)

  • Authors:
  • USP affiliated authors: CAMPOS, MARILIA SILVEIRA DE ALMEIDA - FCFRP ; GOZZO, THAIS DE OLIVEIRA - EERP ; MARTINEZ, EDSON ZANGIACOMI - FMRP ; ANDRADE, JURANDYR MOREIRA DE - FMRP ; PEREIRA, LEONARDO RÉGIS LEIRA - FCFRP
  • USP Schools: FCFRP; EERP; FMRP; FMRP; FCFRP
  • DOI: 10.1007/s11096-015-0070-y
  • Subjects: NEOPLASIAS MAMÁRIAS; FÁRMACOS; QUALIDADE DE VIDA
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    Online accessDOI or search this record in
    Informações sobre o DOI: 10.1007/s11096-015-0070-y (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    Versões disponíveis em Acesso Aberto do: 10.1007/s11096-015-0070-y (Fonte: Unpaywall API)

    Título do periódico: International Journal of Clinical Pharmacy

    ISSN: 2210-7703,2210-7711



      Não possui versão em Acesso aberto
    Informações sobre o Citescore
  • Título: International Journal of Clinical Pharmacy

    ISSN: 2210-7703

    Citescore - 2017: 1.58

    SJR - 2017: 0.702

    SNIP - 2017: 0.857


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    FMRP2711764pcd 2711764 Estantes Deslizantes
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      AYRES, Lorena Rocha; CAMPOS, Marília Silveira de Almeida; GOZZO, Thais de Oliveira; et al. Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital. International Journalof Clinical Pharmacy, Dordrecht, v. 37, n. 2, p. 365-372, 2015. Disponível em: < http://dx.doi.org/10.1007/s11096-015-0070-y > DOI: 10.1007/s11096-015-0070-y.
    • APA

      Ayres, L. R., Campos, M. S. de A., Gozzo, T. de O., Martinez, E. Z., Ungari, A. Q., Andrade, J. M., & Pereira, L. R. L. (2015). Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital. International Journalof Clinical Pharmacy, 37( 2), 365-372. doi:10.1007/s11096-015-0070-y
    • NLM

      Ayres LR, Campos MS de A, Gozzo T de O, Martinez EZ, Ungari AQ, Andrade JM, Pereira LRL. Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital [Internet]. International Journalof Clinical Pharmacy. 2015 ; 37( 2): 365-372.Available from: http://dx.doi.org/10.1007/s11096-015-0070-y
    • Vancouver

      Ayres LR, Campos MS de A, Gozzo T de O, Martinez EZ, Ungari AQ, Andrade JM, Pereira LRL. Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital [Internet]. International Journalof Clinical Pharmacy. 2015 ; 37( 2): 365-372.Available from: http://dx.doi.org/10.1007/s11096-015-0070-y

    Referências citadas na obra
    Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.
    Instituto Nacional do Câncer. Estimativa 2012: Incidência de Câncer no Brasil. Rio de Janeiro: Ministério da Saúde; 2011.
    Lee BL, Liedke PE, Barrios CH, et al. Breast cancer in Brazil: present status and future goals. Lancet Oncol. 2012;13:e95–102.
    Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2-2/neu oncogene. Science. 1987;235:177–82.
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:789–92.
    Murphy CG, Modi S. HER2 breast cancer therapies: a review. Biologics. 2009;3:289–301.
    Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37(Suppl 4):S3–8.
    Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.
    Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14:320–68.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–72.
    Procter M, Suter TM, de Azambuja E, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol. 2010;28:3422–8.
    de Azambuja E, Bedard PL, Suter T, Piccart-Gebhart M. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Target Oncol. 2009;4:77–88.
    Guglin M, Hartlage G, Reynolds C, et al. Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study. J Card Fail. 2009;15:651–7.
    Wadhwa D, Fallah-Rad N, Grenier D, et al. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat. 2009;117:357–64.
    Tarantini L, Cioffi G, Gori S, et al. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail. 2012;18:113–19.
    Farolfi A, Melegari E, Aquilina M, et al. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart. 2013;99:634–9.
    Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (HCFMRP/USP). http://www.hcrp.fmrp.usp.br/sitehc/informacao.aspx?id=5&ref=1&refV=1 . Last accessed 26 May 2013.
    Brasil. Portaria nº 741 de 19 de dezembro de 2005. http://portal.anvisa.gov.br/wps/wcm/connect/3092aa80474594909c3fdc3fbc4c6735/PORTARIA+N%C2%BA+741-2005.pdf?MOD=AJPERES . Last accessed 26 May 2013.
    Ministério da Saúde. http://portal.saude.gov.br/portal/arquivos/pdf/Trastuzumabe_caavancado_final.pdf . Last accessed 26 May 2013.
    Allison PD. Logistic regression using the SAS system: theory and application. Cary: SAS Books; 2001.
    Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson Cancer Center experience. J Clin Oncol. 2006;24:4107–15.
    Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 1995;353:1673–84.
    Aogi K, Saeki T, Nakamura S, et al. A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study). Int J Clin Oncol. 2012;. doi: 10.1007/s10147-012-0437-1 .
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trial. Lancet. 2012;379:432–44.
    Roca-Alonso L, Pellegrino L, Castellano L, et al. Breast cancer treatment and adverse cardiac events: what are the molecular mechanisms? Cardiology 2012;122:253–59.
    Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339:900–5.
    Di Cosimo S. Heart to heart with trastuzumab: a review on cardiac toxicity. Target Oncol. 2011;6:189–95.
    Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23:7820–6.
    Chen T, Xu T, Li Y, et al. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev. 2011;37:312–20.
    Dent S, Hopkins S, Graham N. The experience of a multidisciplinary clinic in the management of early-stage breast cancer patients receiving trastuzumab therapy: an observational study. Cardiol Res Pract. 2012;2012:135819. doi: 10.1155/2012/135819 .
    Serrano C, Cortés J, De Mattos-Arruda L, et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol. 2012;23:897–902.
    van Hasselt JG, Boekhout AH, Beijnen JH, et al. Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity. Clin Pharmacol Ther. 2011;90:126–32.
    Fox KF. The evaluation of left ventricular function for patients being considered for, or receiving trastuzumab (Herceptin) therapy. Br J Cancer. 2006;95:1454.
    Ministério da Saúde. http://portal.saude.gov.br/portal/arquivos/pdf/Relatorio_Trastuzumabe_ca_inicial.pdf . Last accessed 26 May 2013.